Publication Cover
Xenobiotica
the fate of foreign compounds in biological systems
Volume 32, 2002 - Issue 8
59
Views
11
CrossRef citations to date
0
Altmetric
Research Article

Pharmacokinetics and metabolism of the anti-oestrogen droloxifene in female human subjects

, , , , , & show all
Pages 699-713 | Published online: 22 Sep 2008
 

Abstract

1. Single oral doses of a solution formulation of 14 C-droloxifene citrate (141 mg) appeared to be rapidly and well absorbed in four post-menopausal female subjects. Peak plasma concentrations (C max) of total 14 C (1260 ng eq. ml -1), droloxifene (196 ng ml -1) and the major metabolite droloxifene glucuronide (851ng eq. ml -1) occurred at 0.9-1.1h (T max) and declined bi-exponentially with terminal half-lives of 45.0, 31.6 and 32.0h respectively. The mean AUCs of droloxifene and the major metabolite were 21 and 37% respectively that of total 14 C. 2. Total 14 C was excreted slowly, mainly in the faeces. Mean totals of 6.6 and 90.3% of the dose were excreted in the urine and faeces respectively during 11 days. The data were consistent with biliary excretion and enterohepatic circulation of the major metabolite, droloxifene glucuronide. 3. GC-MS showed that the major 14 C-components in 0-24-h urine were droloxifene (mean 0.4% dose) and its glucuronide (2.3% dose), and in faeces were droloxifene (60.2% dose) and N- desmethyldroloxifene (4.2% dose). Other components in faeces corresponded chromatographically to reference standards, droloxifene N -oxide (1.9% dose), side-chain hydroxylated droloxifene (dimethylamine moiety of droloxifene side-chain replaced by hydroxyl, 1.3% dose) and droloxifene glucuronide (10.7% dose). The latter was resistant to enzymic hydrolysis by the β -glucuronidase used. 4. Intersubject variability in the pharmacokinetics of droloxifene in this study was relatively low (CV < 20% for AUC and half-life).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.